Resources for Researchers : All NIDDK Standardization Programs
Clinical trials of agents to preserve beta cell function in new onset type 1 diabetes will use C-peptide as an outcome measure that indicates insulin production. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials.
For more information, contact Dr. Lisa Spain, DEM, Director, Immunobiology of Type 1 Diabetes Program and Autoimmune Endocrine Diseases Program.
|Creatinine Standardization Program, Laboratory Professionals|
The NKDEP Laboratory Working Group has launched the Creatinine Standardization Program to address inter-laboratory variation in creatinine assay calibration and provide more accurate estimates of GFR.
For more information, contact Dr. Andrew Narva, Director, National Kidney Disease Education Program; Senior Scientific Advisor.
|Diabetes Autoantibody Standardization Program (DASP)|
The fundamental aim of DASP is to improve the measurements of the autoantibodies predictive of type 1 diabetes.
For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.
|National Glycohemoglobin Standardization Program (NGSP)|
The goal of this project is to improve HbA1c measurements and data interpretation across clinical systems and national harmonization projects.
Page last updated: December 15, 2008